These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 26523771)

  • 21. [Recording and reporting adverse reactions in clinical trials. New legal provisions according to the 12th Law Amending the German Drug Law (AMG) and the Ordinance on GCP (GCP-V)].
    Eckhardt K; Cremer-Schaeffer P; König J; Paeschke N
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):173-80. PubMed ID: 15726458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ObTiMA system - ontology-based managing of clinical trials.
    Stenzhorn H; Weiler G; Brochhausen M; Schera F; Kritsotakis V; Tsiknakis M; Kiefer S; Graf N
    Stud Health Technol Inform; 2010; 160(Pt 2):1090-4. PubMed ID: 20841852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving the quality of reporting of randomized controlled trials evaluating herbal interventions: implementing the CONSORT statement [corrected].
    Gagnier J; Boon H; Rochon P; Barnes J; Moher D; Bombardier C;
    Explore (NY); 2006 Mar; 2(2):143-9. PubMed ID: 16781628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient safety organizations can help providers improve performance and results.
    Gosfield AG
    Med Econ; 2014 Jan; 91(2):44-6, 48. PubMed ID: 25211957
    [No Abstract]   [Full Text] [Related]  

  • 26. Using historical control information for the design and analysis of clinical trials with overdispersed count data.
    Gsteiger S; Neuenschwander B; Mercier F; Schmidli H
    Stat Med; 2013 Sep; 32(21):3609-22. PubMed ID: 23722585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of Cell and Gene Therapy Medicinal Products in Taiwan.
    Lin YC; Wang PY; Tsai SC; Lin CL; Tai HY; Lo CF; Wu SI; Chiang YM; Liu LL
    Adv Exp Med Biol; 2015; 871():181-94. PubMed ID: 26374219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data.
    Nelson JC; Cook AJ; Yu O; Dominguez C; Zhao S; Greene SK; Fireman BH; Jacobsen SJ; Weintraub ES; Jackson LA
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():62-71. PubMed ID: 22262594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Participants' perspectives on safety monitoring in clinical trials.
    Flynn KE; Kramer JM; Dombeck CB; Weinfurt KP
    Clin Trials; 2013 Aug; 10(4):552-9. PubMed ID: 23644503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Risk-benefit evaluation of medicinal products. An element of Health Technology Assessment].
    Hart D
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):204-14. PubMed ID: 15726462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A clinical trial primer: historical perspective and modern implementation.
    Karsh LI
    Urol Oncol; 2012; 30(4 Suppl):S28-32. PubMed ID: 22795078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complication rates of ventricular tachycardia ablation: Comparison of safety outcomes derived from administrative databases and clinical trials.
    Pothineni NV; Deshmukh A; Padmanabhan D; Kovelamudi S; Patel NJ; Badheka AO; Mulpuru SK; Paydak H; Noseworthy PA
    Int J Cardiol; 2015 Dec; 201():529-31. PubMed ID: 26322600
    [No Abstract]   [Full Text] [Related]  

  • 35. New European regulation for clinical trials of medicinal products.
    Lemaire F; Matei M; Juvin P
    Am J Respir Crit Care Med; 2015 Jan; 191(1):16-8. PubMed ID: 25551347
    [No Abstract]   [Full Text] [Related]  

  • 36. The Cardiac Safety Research Consortium ECG database.
    Kligfield P; Green CL
    J Electrocardiol; 2012; 45(6):690-2. PubMed ID: 22999491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Requirements for Clinical Trials with Gene Therapy and Transplant Products in Switzerland.
    Marti A
    Adv Exp Med Biol; 2015; 871():131-45. PubMed ID: 26374216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploratory clinical trials: implementation modes & guidelines, scope and regulatory framework.
    Francillon A; Pickering G; Belorgey C
    Therapie; 2009; 64(3):149-59. PubMed ID: 19671427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory Oversight of Cell- and Tissue-Based Therapeutic Products and Gene Therapy Products in Singapore.
    Goh CW; Kellathur SN; Ong LL; Wu X
    Adv Exp Med Biol; 2015; 871():195-212. PubMed ID: 26374220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 3: Porcine islet product manufacturing and release testing criteria.
    Rayat GR; Gazda LS; Hawthorne WJ; Hering BJ; Hosking P; Matsumoto S; Rajotte RV
    Xenotransplantation; 2016; 23(1):38-45. PubMed ID: 26923763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.